Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.56 |
| ▸ | BRAF | P15056 | 8/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | IL18 | Q14116 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 4/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473528 | 0.91 | KDR (0.47) | KDRBRAFKITRAF1EPHX2 | |
| SCHEMBL3366948 | 0.91 | KDR (0.48) | KDRBRAFKITRAF1EPHX2 | |
| SCHEMBL13363778 | 0.91 | KDR (0.47) | KDRBRAFKITKMT2ARAB9A | |
| SCHEMBL13363759 | 0.91 | KDR (0.53) | KDRBRAFKITRAF1EPHX2 | |
| SCHEMBL13363760 | 0.90 | KDR (0.46) | KDRBRAFMET | |
| SCHEMBL13799389 | 0.90 | KDR (0.46) | KDRBRAFKITRAF1EPHX2 | |
| SCHEMBL13363771 | 0.90 | KDR (0.45) | KDRBRAFKITRAF1MAPK14 | |
| SCHEMBL13363783 | 0.90 | KDR (0.51) | KDRBRAFKITMEN1KMT2A | |
| SCHEMBL13363761 | 0.90 | KDR (0.45) | KDRBRAFKITRAF1HDAC3 | |
| SCHEMBL1379400 | 0.89 | KDR (0.46) | KDRBRAFKITRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-18 | — | — | US | disclosed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | CDK4, MKI67, TP53 | KDR 135/4885BRAF 154/4885KIT 389/4885 |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | CDK4, MKI67, TP53 | KDR 135/4885BRAF 154/4885KIT 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.